FASEB J. Mp Biomedicals
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published as doi: 10.1096/fj.07-8697rev.
(The FASEB Journal. 2007;21:3795-3808.)
© 2007 FASEB
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
fj.07-8697revv1
21/14/3795    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Basavapathruni, A.
Right arrow Articles by Anderson, K. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Basavapathruni, A.
Right arrow Articles by Anderson, K. S.

Reverse transcription of the HIV-1 pandemic

Aravind Basavapathruni1 and Karen S. Anderson2

Yale University School of Medicine, Department of Pharmacology, New Haven, Connecticut, USA

2Correspondence: Yale University School of Medicine, Department of Pharmacology, SHM B350B, 333 Cedar St., New Haven, CT 06520-8066, USA. E-mail: karen.anderson{at}yale.edu

The HIV/AIDS pandemic has existed for >25 years. Extensive work globally has provided avenues to combat viral infection, but the disease continues to rage on in the human population and infected ~4 million people in 2006 alone. In this review, we provide a brief history of HIV/AIDS, followed by analysis of one therapeutic target of HIV-1: its reverse transcriptase (RT). We discuss the biochemical characterization of RT in order to place emphasis on possible avenues of inhibition, which now includes both nucleoside and non-nucleoside modalities. Therapies against RT remain a cornerstone of anti-HIV treatment, but the virus eventually resists inhibition through the selection of drug-resistant RT mutations. Current inhibitors and associated resistance are discussed, with the hopes that new therapeutics can be developed against RT.—Basavapathruni, A., Anderson, K. S. Reverse transcription of the HIV-1 pandemic.


Key Words: resistance • nucleoside • non-nucleoside • AIDS • NRTI removal




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
T. Matamoros, M. Nevot, M. A. Martinez, and L. Menendez-Arias
Thymidine Analogue Resistance Suppression by V75I of HIV-1 Reverse Transcriptase: EFFECTS OF SUBSTITUTING VALINE 75 ON STAVUDINE EXCISION AND DISCRIMINATION
J. Biol. Chem., November 20, 2009; 284(47): 32792 - 32802.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. P. Tchesnokov, A. Obikhod, I. Massud, A. Lisco, C. Vanpouille, B. Brichacek, J. Balzarini, C. McGuigan, M. Derudas, L. Margolis, et al.
Mechanisms Associated with HIV-1 Resistance to Acyclovir by the V75I Mutation in Reverse Transcriptase
J. Biol. Chem., August 7, 2009; 284(32): 21496 - 21504.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
C. Garriga, M. J. Perez-Elias, R. Delgado, L. Ruiz, L. Perez-Alvarez, T. Pumarola, A. Lopez-Lirola, J. Gonzalez-Garcia, L. Menendez-Arias, and on behalf of the Spanish Group for the Study of An
HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations
J. Antimicrob. Chemother., August 1, 2009; 64(2): 251 - 258.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
B. Romani and S. Engelbrecht
Human immunodeficiency virus type 1 Vpr: functions and molecular interactions
J. Gen. Virol., August 1, 2009; 90(8): 1795 - 1805.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Ehteshami, B. J. Scarth, E. P. Tchesnokov, C. Dash, S. F. J. Le Grice, S. Hallenberger, D. Jochmans, and M. Gotte
Mutations M184V and Y115F in HIV-1 Reverse Transcriptase Discriminate against "Nucleotide-competing Reverse Transcriptase Inhibitors"
J. Biol. Chem., October 31, 2008; 283(44): 29904 - 29911.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by The Federation of American Societies for Experimental Biology.